CAS 1020149-73-8

SGI-1027

Description:

SGI-1027, with the CAS number 1020149-73-8, is a small molecule that has garnered attention in the field of medicinal chemistry, particularly for its potential as an epigenetic modulator. It functions primarily as a DNA methyltransferase inhibitor, which means it can interfere with the addition of methyl groups to DNA, a process that plays a crucial role in gene expression regulation. By inhibiting this process, SGI-1027 may reactivate silenced genes, making it a candidate for therapeutic applications in various diseases, including cancer. The compound is characterized by its ability to selectively target specific methyltransferases, which may lead to fewer side effects compared to broader-spectrum agents. Additionally, SGI-1027 has been studied for its effects on cellular pathways and its potential to enhance the efficacy of other treatments. Its solubility, stability, and bioavailability are important factors that influence its pharmacological profile and therapeutic potential. Overall, SGI-1027 represents a promising avenue for research in epigenetic therapies.

N-(4-((2-Amino-6-Methylpyrimidin-4-Yl)Amino)Phenyl)-4-(Quinolin-4-Ylamino)Benzamide

CAS: 1020149-73-8

N-(4-((2-Amino-6-Methylpyrimidin-4-Yl)Amino)Phenyl)-4-(Quinolin-4-Ylamino)Benzamide

Formula: C₂₇H₂₃N₇O

Purity: ≥98%

Molecular weight: 461.52

Ref: 54-OR1023745

SGI-1027

CAS: 1020149-73-8

SGI-1027

Formula: C₂₇H₂₃N₇O

Purity: ≥98%

Molecular weight: 461.52

Ref: 54-BUP10680

Benzamide, N-[4-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenyl]-4-(4-quinolinylamino)-

CAS: 1020149-73-8

Formula: C₂₇H₂₃N₇O

Purity: 98%

Color and Shape: Solid

Molecular weight: 461.5178

Ref: IN-DA0006BW

SGI-1027

CAS: 1020149-73-8

SGI-1027 (DNA Methyltransferase Inhibitor II) is an effective and selective inhibitor of DNA methyltransferase (DNMT).

Formula: C₂₇H₂₃N₇O

Purity: 99.45% - 99.78%

Color and Shape: Solid

Molecular weight: 461.52

Ref: TM-T1904

SGI-1027

Controlled Product

CAS: 1020149-73-8

Applications SGI-1027 is a quinoline derivative and a potent inhibitor of DNA methyltransferase (DNMT). SGI-1027 can be used as a potential therapeutic agent for the treatment of cancer and other diseases and also as a research tool to investigate the role of DNMTs in epigenetic events.
References Rilova, E., et al.: Chem. Med. Chem., 9, 590 (2014); Yoo, J., et al.: PLoS One, 8, e62152 (2013); Medina-Franco, J.L., et al.: Mol. Divers., 17, 337 (2013); Yoo, J., et al.: Curr. Comput-aid. Drug, 8, 317 (2012)

Formula: C₂₇H₂₃N₇O

Color and Shape: Neat

Molecular weight: 461.518

Ref: TR-S282375

SGI-1027

CAS: 1020149-73-8

N-(4-((2-Amino-6-methylpyrimidin-4-yl)amino)phenyl)-4-(quinolin-4-ylamino)benzamide

Formula: C₂₇H₂₃N₇O

Purity: 98%

Molecular weight: 461.52

Ref: IN-DG305455

Benzamide, N-[4-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenyl]-4-(4-quinolinylamino)-

CAS: 1020149-73-8

Purity: 98%

Molecular weight: 461.5289917

Ref: 10-F865516

SGI-1027

CAS: 1020149-73-8

SGI-1027 is a methyltransferase inhibitor that has been shown to inhibit the expression of cancer genes in vitro. It also inhibits tumor growth in experimental models, and has significant cytotoxicity against cervical cancer cells. SGI-1027 inhibits the function of toll-like receptor 9 (TLR9) by inhibiting the binding of TLR9 to its ligands, which are found on bacteria and viruses. This inhibition prevents TLR9 from stimulating dendritic cells and macrophages to produce proinflammatory cytokines such as IL-1β, TNFα, IL-6, and IL-12. SGI-1027 also reduces the production of reactive oxygen species (ROS), which are implicated in many diseases including autoimmune diseases.

Formula: C₂₇H₂₃N₇O

Purity: Min. 95%

Molecular weight: 461.52 g/mol

Ref: 3D-VQB14973